Umut KEFELİ, Dincer AYDIN, Nur ŞENER, Mahmut GÜMÜS, Mehmet ALİUSTAOĞLU, Bala Basak USTAALİOĞLU ÖVEN, Burçak YILMAZ

Non-small cell lung cancer in women: A distinct entity?

Amaç: Akciğer kanseri her iki cinsiyette de kanser ile ilişkili önde gelen ölüm nedenlerinden biridir ve tüm dünyada giderek artmaktadır. Birçok çalışmada insidans ve mortalitedeki bu artış cinsiyet, tümör tipi ve hastaların klinik karakteristikleri ile ilişkili bulunmuştur. Bu çalışmanın amacı kadın küçük hücreli dışı akciğer kanserli (KHDAK) hastalarda klinik özellik farklılıklarını ve prognostik faktörleri araştırmaktır. Gereç ve Yöntem: 2005-2012 yılları arasında 893 KHDAKlı hastanın verileri geriye yönelik incelendi. Hastaların 773ü erkek (%86.5) ve 120si (%13.5) kadındı. Hastaların demografik verileri, histolojik tipleri, klinik evreleri, semptomları ve tedavi modaliteleri incelendi. Sağkalım Kaplan-Meier metodu ve prognostik faktörler log-rank ve Cox regresyon testleri ile analiz edildi. Bulgular: Kadın hastaların medyan yaşı 60.6 idi. Erkek hastalarda sigara öyküsü olanların oranı % 89.6 iken, kadın hastalarda bu oran % 44.9 olarak bulundu. Kadınlarda en sık tümör tipi adenokarsinom (%32.7),erkeklerde skuamöz hücreli karsinomdu (%34.0). Kadın hastaların medyan genel sağkalımı 13.7 ay, erkek hastaların 10.9 ay olarak saptandı (p>0.05). Tek değişkenli analizlerde kadın hastalarda yaş, kilo kaybı, kombinasyon tedavisi ve performans statüsü sağkalımı artıran faktörlerdi. Çok değişkenli analizlerde kadın hastalarda sağkalım ile ilşkili tek faktör iyi performans statüsüydü. Sonuç: Kadınlarda KHDAK erkeklere göre farklıdır. Kadınlarda adenokarsinom daha sıktır ve KHDAK daha iyi prognozludur. Kadın KHDAKnin daha detaylı anlaşılması yeni tedavi ve prevensiyon stratejelerinin geliştirilmesine olanak sağlayacaktır.

Kadınlarda küçük hücreli dışı akciğer kanseri: Farklı bir antite mi?

Aim: Lung cancer is one of the major causes of cancer-related deaths in both sexes and increasing worldwide. In many studies this increase in incidence and mortality was related to the sex, tumor type and clinical characteristics of the patients. The aim of this study was to evaluate the differences in clinical features and the prognostic factors in our female patients with NSCLC. Methods: We retrospectively analyzed the records of our 893 patients with non-small cell lung cancer (NSCLC) from 2005 to 2012. Of these, 773 were male (86.5%) and 120 were female (13.5%) patients. The data included demographic information, histologic classification, clinical staging, presenting symptoms and treatment modalities. Survival was estimated by using Kaplan Meier method and prognostic factors were evaluated with log-rank and Cox regression tests. Results: The median age of the female patients was 60.6. The percent of the male and female patients that had a smoking history was 89.6% and 44.9%, respectively. Most common tumor type in female patients was adenocarcinoma (32.7%) and in male patients was squamos cell carcinoma (34.0%). The median survival time for female patients was 13.7 months and for the male patients it was 10.9 months (p>0.05). In univariate analysis, age, weight loss, combination therapy and PS correlated with a better OS for female patients. In multivariate analysis, only good PS showed consistency with survival for women. Conclusion: NSCLC in women is different in women as compared with men. Women are more likely to develop adenocarcinoma of the lung and have more favorable prognosis. A more through understanding of the NSCLC in women may lead to new treatment and prevention strategies.

PDF

___

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 453944.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):1130.
3. Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 2005;128: 370-81.
4. Giovino GA. Epidemiology of tobacco use in the United States. Oncogene 2002; 21: 7326-40.
5. Patel JD. Lung cancer in women. J Clin Oncol 2005; 23: 3212-8.
6. Sen E, Kaya A, Erol S, Savas I, Gonullu U. Lung cancer in women: clinical features and factors related to survival. Tuberk Toraks 2008; 56: 266-74.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 64955.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205 16.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 20714.
10. Ramalingam S, Pawlish K, Gadgeel S. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results Database. Am J Clin Oncol 1998; 16: 651-57.
11. Rivera MP, Stover DE. Gender and lung cancer. Clin Chest Med 2004; 25: 391-400.
12. Lienert T, Serke M, Schönfeld R, Loddenkemper R. Lung cancer in young females. Eur Respir J 2000; 16: 986-90.
13. Huhti E, Sutinen S, Reinila A, et al. Lung cancer in a defined geographical area: History and histological types. Thorax 1980; 35: 660-7.
14. Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer 1996; 77: 1947-55.
15. Coggon D, Acheson ED. Trends in lung cancer mortality. Thorax 1983; 38 : 721-3.
16. Satcher D, Thompson TG, Koplan JP. Women and smoking: a report of the Surgeon General. Nicotine Tob Res 2002; 4: 7-20.
17. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88 :18392.
18. Henschke CI, Miettinen OS. Womens susceptibility to tobacco carcinogens. Lung Cancer 2004; 43: 15.
19. Bain C, Feskanich D, Speizer F, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96: 82634.
20. Montesinos J, Bare M, Dalmau E, et al. The changing pattern of non-small cell lung cancer between the 90 and 2000 decades. Open Respir Med J 2011; 5: 24-30.
21. National Cancer Institute 2009. Bethesda M. SEER Cancer Statistics Review, 1975-2006. Online source. Avalaible at http://seer.cancer.gov/csr/1975_2006/.
22. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 2949.
23. Hatcher J, Dover DC. Trends in histopathology of lung cancer in Alberta. Can J Public Health 2003; 94: 2926.
24. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997; 89: 1580-6.
25. Ferguson MK, Skosey C, Hoffman PC, et al . Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990; 8: 1402-7.
26. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival: population-based study of 20,561 cases. Ann Oncol 2002; 13: 108793.
27. Albain KS, Rusch VW, Crowley JJ. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-92.
28. Albain KS, Crowley JJ, LeBlanc M. Survival determinants in extensive- stage non-small cell lung cancer: the Southwest Oncology Group experience. Am J Clin Oncol 1991; 9: 1618-26.
29. Paesmans M, Sculier JP, Libert G. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995; 13: 1221-30.